Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients

Abi VijenthiraPostgraduate Medical Education, University of Toronto, Toronto, Canada;

Manjula MagantiDepartment of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada;

Vishal KukretiDivision of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

John KuruvillaDivision of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Rodger TiedemannDivision of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Christine ChenDivision of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Michael CrumpDivision of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Anca PricaDivision of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, CanadaCorrespondence[email protected]

show all

Click to increase image sizeClick to decrease image size

Acknowledgments

This work was supported by the American Society of Hematology HONORS (Hematology Opportunities for the Next Generation of Research Scientists) Award.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2019.1585837.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients

Information for

Open access

Opportunities

Help and information

Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients

Acknowledgments

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature